Which has better valuation and earnings, IVA or DERM?

Journey Medical has higher revenue and earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inventiva $5.07M 160.19 -$400.67M N/A N/A Journey Medical $64.68M 3.02 -$11.43M -$0.37 N/A

Does the media favor IVA or DERM?

In the previous week, Inventiva had 1 more articles in the media than Journey Medical. MarketBeat recorded 3 mentions for Inventiva and 2 mentions for Journey Medical. Inventiva's average media sentiment score of 0.23 beat Journey Medical's score of 0.00 indicating that Inventiva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Journey Medical 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer DERM or RLMD?

In the previous week, Journey Medical and Journey Medical both had 2 articles in the media. Relmada Therapeutics' average media sentiment score of 0.13 beat Journey Medical's score of 0.00 indicating that Relmada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Journey Medical 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Relmada Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AURA or DERM?

In the previous week, Journey Medical had 1 more articles in the media than Aura Biosciences. MarketBeat recorded 2 mentions for Journey Medical and 1 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 1.97 beat Journey Medical's score of 0.00 indicating that Aura Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aura Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Journey Medical 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Journey Medical (DERM) Competitors

$7.09 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$7.09 0.00 (0.00%)

As of 07/2/2026 04:10 PM Eastern

Compare

DERM vs. FBIO, IVA, RLMD, GYRE, and AURA

Should you buy Journey Medical stock or one of its competitors? MarketBeat compares Journey Medical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Journey Medical include Fortress Biotech (FBIO), Inventiva (IVA), Relmada Therapeutics (RLMD), Gyre Therapeutics (GYRE), and Aura Biosciences (AURA). These companies are all part of the "medical" sector.

How does Journey Medical compare to Fortress Biotech?

Fortress Biotech (NASDAQ:FBIO) and Journey Medical (NASDAQ:DERM) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

Fortress Biotech has higher earnings, but lower revenue than Journey Medical. Journey Medical is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$63.26M	1.60	$6.82M	$3.17	0.96
Journey Medical	$64.68M	3.02	-$11.43M	-$0.37	N/A

In the previous week, Journey Medical had 2 more articles in the media than Fortress Biotech. MarketBeat recorded 2 mentions for Journey Medical and 0 mentions for Fortress Biotech. Fortress Biotech's average media sentiment score of 0.00 equaled Journey Medical'saverage media sentiment score.

Company	Overall Sentiment
Fortress Biotech	Neutral
Journey Medical	Neutral

96.5% of Fortress Biotech shares are held by institutional investors. Comparatively, 7.3% of Journey Medical shares are held by institutional investors. 28.5% of Fortress Biotech shares are held by insiders. Comparatively, 14.5% of Journey Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Fortress Biotech has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market. Comparatively, Journey Medical has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market.

Fortress Biotech has a net margin of 193.12% compared to Journey Medical's net margin of -14.82%. Fortress Biotech's return on equity of 109.66% beat Journey Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	193.12%	109.66%	45.56%
Journey Medical	-14.82%	-35.57%	-10.88%

Fortress Biotech currently has a consensus target price of $17.00, suggesting a potential upside of 459.21%. Journey Medical has a consensus target price of $13.00, suggesting a potential upside of 83.36%. Given Fortress Biotech's higher possible upside, analysts plainly believe Fortress Biotech is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Fortress Biotech beats Journey Medical on 10 of the 13 factors compared between the two stocks.

How does Journey Medical compare to Inventiva?

Inventiva (NASDAQ:IVA) and Journey Medical (NASDAQ:DERM) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

In the previous week, Inventiva had 1 more articles in the media than Journey Medical. MarketBeat recorded 3 mentions for Inventiva and 2 mentions for Journey Medical. Inventiva's average media sentiment score of 0.23 beat Journey Medical's score of 0.00 indicating that Inventiva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inventiva	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Journey Medical	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Inventiva has a net margin of 0.00% compared to Journey Medical's net margin of -14.82%. Inventiva's return on equity of 0.00% beat Journey Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Journey Medical	-14.82%	-35.57%	-10.88%

Inventiva currently has a consensus target price of $16.56, suggesting a potential upside of 323.42%. Journey Medical has a consensus target price of $13.00, suggesting a potential upside of 83.36%. Given Inventiva's stronger consensus rating and higher possible upside, analysts clearly believe Inventiva is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Inventiva has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market. Comparatively, Journey Medical has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

19.1% of Inventiva shares are held by institutional investors. Comparatively, 7.3% of Journey Medical shares are held by institutional investors. 32.0% of Inventiva shares are held by company insiders. Comparatively, 14.5% of Journey Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Journey Medical has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$5.07M	160.19	-$400.67M	N/A	N/A
Journey Medical	$64.68M	3.02	-$11.43M	-$0.37	N/A

Summary

Inventiva beats Journey Medical on 12 of the 15 factors compared between the two stocks.

How does Journey Medical compare to Relmada Therapeutics?

Journey Medical (NASDAQ:DERM) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Journey Medical has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market.

Journey Medical currently has a consensus price target of $13.00, indicating a potential upside of 83.36%. Relmada Therapeutics has a consensus price target of $12.00, indicating a potential upside of 91.08%. Given Relmada Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Relmada Therapeutics is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Journey Medical and Journey Medical both had 2 articles in the media. Relmada Therapeutics' average media sentiment score of 0.13 beat Journey Medical's score of 0.00 indicating that Relmada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Journey Medical	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Relmada Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Journey Medical has higher revenue and earnings than Relmada Therapeutics. Journey Medical is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Journey Medical	$64.68M	3.02	-$11.43M	-$0.37	N/A
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A

7.3% of Journey Medical shares are held by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are held by institutional investors. 14.5% of Journey Medical shares are held by insiders. Comparatively, 14.5% of Relmada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Relmada Therapeutics has a net margin of 0.00% compared to Journey Medical's net margin of -14.82%. Journey Medical's return on equity of -35.57% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Journey Medical	-14.82%	-35.57%	-10.88%
Relmada Therapeutics	N/A	-71.22%	-64.46%

Summary

Relmada Therapeutics beats Journey Medical on 8 of the 15 factors compared between the two stocks.

How does Journey Medical compare to Gyre Therapeutics?

Gyre Therapeutics (NASDAQ:GYRE) and Journey Medical (NASDAQ:DERM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

24.0% of Gyre Therapeutics shares are owned by institutional investors. Comparatively, 7.3% of Journey Medical shares are owned by institutional investors. 9.5% of Gyre Therapeutics shares are owned by company insiders. Comparatively, 14.5% of Journey Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Journey Medical had 2 more articles in the media than Gyre Therapeutics. MarketBeat recorded 2 mentions for Journey Medical and 0 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 0.00 equaled Journey Medical'saverage media sentiment score.

Company	Overall Sentiment
Gyre Therapeutics	Neutral
Journey Medical	Neutral

Gyre Therapeutics currently has a consensus price target of $17.00, suggesting a potential upside of 131.61%. Journey Medical has a consensus price target of $13.00, suggesting a potential upside of 83.36%. Given Gyre Therapeutics' higher probable upside, equities research analysts clearly believe Gyre Therapeutics is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Gyre Therapeutics has a beta of 1.89, indicating that its stock price is 89% more volatile than the broader market. Comparatively, Journey Medical has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

Gyre Therapeutics has higher revenue and earnings than Journey Medical. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Journey Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$117.05M	6.99	$5.03M	-$0.09	N/A
Journey Medical	$64.68M	3.02	-$11.43M	-$0.37	N/A

Gyre Therapeutics has a net margin of -5.44% compared to Journey Medical's net margin of -14.82%. Gyre Therapeutics' return on equity of 3.13% beat Journey Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-5.44%	3.13%	2.67%
Journey Medical	-14.82%	-35.57%	-10.88%

Summary

Gyre Therapeutics beats Journey Medical on 10 of the 14 factors compared between the two stocks.

How does Journey Medical compare to Aura Biosciences?

Aura Biosciences (NASDAQ:AURA) and Journey Medical (NASDAQ:DERM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

Aura Biosciences has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market. Comparatively, Journey Medical has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market.

96.8% of Aura Biosciences shares are owned by institutional investors. Comparatively, 7.3% of Journey Medical shares are owned by institutional investors. 1.9% of Aura Biosciences shares are owned by company insiders. Comparatively, 14.5% of Journey Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Aura Biosciences has a net margin of 0.00% compared to Journey Medical's net margin of -14.82%. Journey Medical's return on equity of -35.57% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-78.12%	-64.08%
Journey Medical	-14.82%	-35.57%	-10.88%

Journey Medical has higher revenue and earnings than Aura Biosciences. Journey Medical is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A
Journey Medical	$64.68M	3.02	-$11.43M	-$0.37	N/A

Aura Biosciences currently has a consensus price target of $20.50, indicating a potential upside of 164.86%. Journey Medical has a consensus price target of $13.00, indicating a potential upside of 83.36%. Given Aura Biosciences' higher possible upside, research analysts clearly believe Aura Biosciences is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Journey Medical had 1 more articles in the media than Aura Biosciences. MarketBeat recorded 2 mentions for Journey Medical and 1 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 1.97 beat Journey Medical's score of 0.00 indicating that Aura Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aura Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Journey Medical	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Journey Medical beats Aura Biosciences on 8 of the 13 factors compared between the two stocks.

Get Journey Medical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DERM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DERM vs. The Competition

Export

Metric	Journey Medical	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$195.22M	$3.10B	$7.16B	$12.48B
Dividend Yield	N/A	2.05%	2.66%	6.52%
P/E Ratio	-19.16	20.06	28.02	24.70
Price / Sales	3.02	360.33	540.37	99.46
Price / Cash	N/A	57.49	49.26	57.09
Price / Book	7.39	4.32	10.96	6.46
Net Income	-$11.43M	$64.45M	$3.57B	$337.01M
7 Day Performance	7.10%	2.97%	2.12%	1.69%
1 Month Performance	18.76%	6.83%	5.25%	3.81%
1 Year Performance	-0.14%	29.07%	33.29%	23.90%

Journey Medical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DERM Journey Medical	1.7197 of 5 stars	$7.09 flat	$13.00 +83.4%	-0.1%	$195.22M	$64.68M	N/A	90	News Coverage
FBIO Fortress Biotech	1.623 of 5 stars	$3.06 +3.7%	$17.00 +455.6%	+59.2%	$98M	$63.26M	0.97	170
IVA Inventiva	2.7478 of 5 stars	$3.78 +6.5%	$16.56 +338.0%	+27.8%	$737.36M	$5.07M	N/A	100	Options Volume Gap Down
RLMD Relmada Therapeutics	1.9721 of 5 stars	$6.92 -0.9%	$12.00 +73.4%	+901.6%	$732.13M	N/A	N/A	10	Gap Up
GYRE Gyre Therapeutics	1.7971 of 5 stars	$6.59 +2.2%	$17.00 +158.0%	-9.8%	$719.10M	$116.59M	N/A	40	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DERM) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Journey Medical (DERM) Competitors

DERM vs. FBIO, IVA, RLMD, GYRE, and AURA

How does Journey Medical compare to Fortress Biotech?

Summary

How does Journey Medical compare to Inventiva?

Summary

How does Journey Medical compare to Relmada Therapeutics?

Summary

How does Journey Medical compare to Gyre Therapeutics?

Summary

How does Journey Medical compare to Aura Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DERM vs. The Competition

Journey Medical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Journey Medical (DERM) Competitors

DERM vs. FBIO, IVA, RLMD, GYRE, and AURA

How does Journey Medical compare to Fortress Biotech?

Which has better earnings & valuation, FBIO or DERM?

Does the media refer more to FBIO or DERM?

Do institutionals and insiders have more ownership in FBIO or DERM?

Which has more risk and volatility, FBIO or DERM?

Is FBIO or DERM more profitable?

Do analysts rate FBIO or DERM?

Summary

How does Journey Medical compare to Inventiva?

Does the media favor IVA or DERM?

Is IVA or DERM more profitable?

Do analysts rate IVA or DERM?

Which has more risk & volatility, IVA or DERM?

Do institutionals & insiders hold more shares of IVA or DERM?

Which has better valuation and earnings, IVA or DERM?

Summary

How does Journey Medical compare to Relmada Therapeutics?

Which has more risk & volatility, DERM or RLMD?

Do analysts prefer DERM or RLMD?

Does the media prefer DERM or RLMD?

Which has higher valuation & earnings, DERM or RLMD?

Do insiders and institutionals believe in DERM or RLMD?

Is DERM or RLMD more profitable?

Summary

How does Journey Medical compare to Gyre Therapeutics?

Do institutionals and insiders have more ownership in GYRE or DERM?

Does the media refer more to GYRE or DERM?

Do analysts recommend GYRE or DERM?

Which has more volatility & risk, GYRE or DERM?

Which has better valuation & earnings, GYRE or DERM?

Is GYRE or DERM more profitable?

Summary

How does Journey Medical compare to Aura Biosciences?

Which has more risk and volatility, AURA or DERM?

Do insiders & institutionals have more ownership in AURA or DERM?

Is AURA or DERM more profitable?

Which has higher valuation & earnings, AURA or DERM?

Do analysts prefer AURA or DERM?

Does the media favor AURA or DERM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DERM vs. The Competition

Journey Medical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools